D-erythro-Sphingosine (synthetic) (Synonyms: (-)Sphingosine, DerythroSphingosine C18) |
| Catalog No.GC17591 |
D-erythro-Sphingosine (synthetic) (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (synthetic) (Erythrosphingosine) is also a PP2A activator.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 123-78-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
D-erythro-sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 value of 8μM[1]. D-erythro-Sphingosine is also a PP2A agonist[2]. D-erythro-sphingosine has been shown to inhibit protein kinase C[3].
D-erythro-sphingosine activated TRPM3 variant containing 1325 aa, independently of PKC inhibition, formation of S1P, or intracellular Ca2+ store depletion[4]. D-erythro-sphingosine lowered the levels of HMG-CoA reductase activity in CHO-K1 cells[5]. D-erythro-sphingosine significantly inhibited mastoparan-, but not Na3VO4-, stimulated arachidonic acid release in PC12 cells. Production of prostaglandin F2α was suppressed by D-erythro-sphingosine (10 μM) in PC12 cells. D-erythro-sphingosine, directly inhibited cytosolic phospholipase A2α activity[6]. A p32-sphingosine-activated protein kinase responded to low concentrations of D-erythro-sphingosine with an initial activation observed at 2.5μM and a peak activity at 10-20μM. This kinase showed a modest specificity for D-erythro-sphingosine over other sphingosine stereoisomers, and a preference for sphingosines over dihydro-sphingosines[1]
D-erythro-sphingosine was identified as one of the most influential factors in ASB-induced nephrotoxicity[7]
References:
[1]. Pushkareva MYu, Bielawska A, et al. Regulation of sphingosine-activated protein kinases: selectivity of activation by sphingoid bases and inhibition by non-esterified fatty acids. Biochem J. 1993;294 ( Pt 3)(Pt 3):699-703.
[2]. Cheng P, Chen K, et al. Protein phosphatase 2A (PP2A) activation promotes axonal growth and recovery in the CNS. J Neurol Sci. 2015;359(1-2):48-56.
[3]. Pham VT, Joo JE, et al. A concise synthesis of a promising protein kinase C inhibitor: D-erythro-sphingosine. Arch Pharm Res. 2007;30(1):22-27.
[4]. Grimm C, Kraft R, et al. Activation of the melastatin-related cation channel TRPM3 by D-erythro-sphingosine [corrected] [published correction appears in Mol Pharmacol. 2005 Apr;67(4):1382]. Mol Pharmacol. 2005;67(3):798-805.
[5]. Pinkerton FD, Kisic A, et al. D-erythro-sphingosine lowers 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in Chinese hamster ovary cells. Biochem Biophys Res Commun. 1993;190(1):63-69.
[6]. Nakamura H, Hirabayashi T, et al. Inhibition of arachidonic acid release and cytosolic phospholipase A2 alpha activity by D-erythro-sphingosine. Eur J Pharmacol. 2004;484(1):9-17.
[7]. Xu JD, Xing WM, et al. Metabolic changes in the urine of andrographolide sodium bisulfite-treated rats. Hum Exp Toxicol. 2016;35(2):162-169.
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *